Sodium-glucose co-transporter 2 (SGLT2) inhibitors are newly established treatments for reducing cardiovascular events in people with T2DM at high CV risk, chronic kidney disease, and heart failure.3, 4, 5 Specific to adults with T2DM, with or without established atherosclerotic CV disease (ASCVD), SGLT2 inhibitors reduced the incidence of CV death or hospitalization for heart failure (HHF) by 32% and reduced the incidence of risk of 3P-MACE by 10%.6 The gene discussed is SLC5A2; the disease is atherosclerosis.